Modeling based response guided therapy in subjects with recent hepatitis C infection

Mathematical modeling of viral kinetics has been shown to identify patients with chronic hepatitis C virus (HCV) infection who could be cured with a shorter duration of direct-acting antiviral (DAA) treatment. However, modeling therapy duration has yet to be evaluated in recently infected individual...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2020-08, Vol.180, p.104862-104862, Article 104862
Main Authors: Gorstein, Evan, Martinello, Marianne, Churkin, Alexander, Dasgupta, Swikriti, Walsh, Kevin, Applegate, Tanya L., Yardeni, David, Etzion, Ohad, Uprichard, Susan L., Barash, Danny, Cotler, Scott J., Matthews, Gail V., Dahari, Harel
Format: Article
Language:English
Subjects:
Direct-acting antivirals
Hepatitis c virus
Mathematical modeling
Recent infection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c452t-a934bb736448e19b8ea04d1ca90dc13f7c12568c1cb5324079e7de806a8353b63
cites cdi_FETCH-LOGICAL-c452t-a934bb736448e19b8ea04d1ca90dc13f7c12568c1cb5324079e7de806a8353b63
container_end_page 104862
container_issue
container_start_page 104862
container_title Antiviral research
container_volume 180
creator Gorstein, Evan
Martinello, Marianne
Churkin, Alexander
Dasgupta, Swikriti
Walsh, Kevin
Applegate, Tanya L.
Yardeni, David
Etzion, Ohad
Uprichard, Susan L.
Barash, Danny
Cotler, Scott J.
Matthews, Gail V.
Dahari, Harel
description Mathematical modeling of viral kinetics has been shown to identify patients with chronic hepatitis C virus (HCV) infection who could be cured with a shorter duration of direct-acting antiviral (DAA) treatment. However, modeling therapy duration has yet to be evaluated in recently infected individuals. The aim of this study was to retrospectively examine whether modeling can predict outcomes of six-week sofosbuvir (SOF) and weight-based ribavirin (R) therapy in individuals with recent HCV infection. Modeling was used to estimate viral host parameters and to predict time to cure for 12 adults with recent HCV infection (
doi_str_mv 10.1016/j.antiviral.2020.104862
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7387218</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016635422030276X</els_id><sourcerecordid>2418118848</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-a934bb736448e19b8ea04d1ca90dc13f7c12568c1cb5324079e7de806a8353b63</originalsourceid><addsrcrecordid>eNqFkU9rGzEQxUVpaZy0n6F77GUd_VutdCkE06SFhF7Ss9BKY1tmLW0lrUO-fbU4BHLKadDMb96I9xD6RvCaYCKuD2sTij_5ZMY1xXTpcinoB7Qisqetwkp8RKtKipZ1nF6gy5wPGGPRK_kZXTDaKSqpWqHHh-hg9GHXDCaDaxLkKYYMzW72rr7LHpKZnhsfmjwPB7AlN0--7CtoIZRmD5MpvvjcbCqzrXMfwxf0aWvGDF9f6hX6e_vzcfOrvf9z93tzc99a3tHSGsX4MPRMcC6BqEGCwdwRaxR2lrBtbwnthLTEDh2jHPcKegcSCyNZxwbBrtCPs-40D0dwy4eqIXpK_mjSs47G67eT4Pd6F0-6Z9UlIqvA9xeBFP_NkIs--mxhHE2AOGdNOZGESMkXtD-jNsWcE2xfzxCsl0z0Qb9mopdM9DmTunlz3oRqxclD0tl6CBacryYW7aJ_V-M_IXeZwQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2418118848</pqid></control><display><type>article</type><title>Modeling based response guided therapy in subjects with recent hepatitis C infection</title><source>ScienceDirect Freedom Collection</source><creator>Gorstein, Evan ; Martinello, Marianne ; Churkin, Alexander ; Dasgupta, Swikriti ; Walsh, Kevin ; Applegate, Tanya L. ; Yardeni, David ; Etzion, Ohad ; Uprichard, Susan L. ; Barash, Danny ; Cotler, Scott J. ; Matthews, Gail V. ; Dahari, Harel</creator><creatorcontrib>Gorstein, Evan ; Martinello, Marianne ; Churkin, Alexander ; Dasgupta, Swikriti ; Walsh, Kevin ; Applegate, Tanya L. ; Yardeni, David ; Etzion, Ohad ; Uprichard, Susan L. ; Barash, Danny ; Cotler, Scott J. ; Matthews, Gail V. ; Dahari, Harel</creatorcontrib><description>Mathematical modeling of viral kinetics has been shown to identify patients with chronic hepatitis C virus (HCV) infection who could be cured with a shorter duration of direct-acting antiviral (DAA) treatment. However, modeling therapy duration has yet to be evaluated in recently infected individuals. The aim of this study was to retrospectively examine whether modeling can predict outcomes of six-week sofosbuvir (SOF) and weight-based ribavirin (R) therapy in individuals with recent HCV infection. Modeling was used to estimate viral host parameters and to predict time to cure for 12 adults with recent HCV infection (&lt;12 months of infection) who received six weeks of treatment with SOF + R. Modeling results yielded a 100% negative predictive value for SOF + R treatment response in nine participants and suggested that a median of 13 [interquartile range: 8–16] weeks of therapy would be required for these patients to achieve cure. Modeling predicted cure after 5 weeks of therapy in the only modeled participant who achieved a sustained virological response. However, cure was also predicted for two participants who relapsed following treatment. The modeling results confirm that longer than 6 weeks of SOF + R is needed to reach cure in individuals with recent HCV infection. Prospective real-time modeling under current potent DAA regimens is needed to validate the potential of response-guided therapy in the management of recent HCV infection. •Modeling identifies chronic hepatitis C patients who were cured with a reduced duration of direct-acting antivirals (DAA).•Duration of DAA treatment has not been previously modeled in persons with recent (&lt;12 months) hepatitis C infection.•We retrospectively modeled ultra-short (6-week) sofosbuvir + ribavirin therapy in recently infected persons.•Modeling might help identify persons with recent hepatitis C who are appropriate for ultra-short duration of DAA therapy.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2020.104862</identifier><identifier>PMID: 32592829</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Direct-acting antivirals ; Hepatitis c virus ; Mathematical modeling ; Recent infection</subject><ispartof>Antiviral research, 2020-08, Vol.180, p.104862-104862, Article 104862</ispartof><rights>2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-a934bb736448e19b8ea04d1ca90dc13f7c12568c1cb5324079e7de806a8353b63</citedby><cites>FETCH-LOGICAL-c452t-a934bb736448e19b8ea04d1ca90dc13f7c12568c1cb5324079e7de806a8353b63</cites><orcidid>0000-0002-3357-1817 ; 0000-0001-5691-1557</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids></links><search><creatorcontrib>Gorstein, Evan</creatorcontrib><creatorcontrib>Martinello, Marianne</creatorcontrib><creatorcontrib>Churkin, Alexander</creatorcontrib><creatorcontrib>Dasgupta, Swikriti</creatorcontrib><creatorcontrib>Walsh, Kevin</creatorcontrib><creatorcontrib>Applegate, Tanya L.</creatorcontrib><creatorcontrib>Yardeni, David</creatorcontrib><creatorcontrib>Etzion, Ohad</creatorcontrib><creatorcontrib>Uprichard, Susan L.</creatorcontrib><creatorcontrib>Barash, Danny</creatorcontrib><creatorcontrib>Cotler, Scott J.</creatorcontrib><creatorcontrib>Matthews, Gail V.</creatorcontrib><creatorcontrib>Dahari, Harel</creatorcontrib><title>Modeling based response guided therapy in subjects with recent hepatitis C infection</title><title>Antiviral research</title><description>Mathematical modeling of viral kinetics has been shown to identify patients with chronic hepatitis C virus (HCV) infection who could be cured with a shorter duration of direct-acting antiviral (DAA) treatment. However, modeling therapy duration has yet to be evaluated in recently infected individuals. The aim of this study was to retrospectively examine whether modeling can predict outcomes of six-week sofosbuvir (SOF) and weight-based ribavirin (R) therapy in individuals with recent HCV infection. Modeling was used to estimate viral host parameters and to predict time to cure for 12 adults with recent HCV infection (&lt;12 months of infection) who received six weeks of treatment with SOF + R. Modeling results yielded a 100% negative predictive value for SOF + R treatment response in nine participants and suggested that a median of 13 [interquartile range: 8–16] weeks of therapy would be required for these patients to achieve cure. Modeling predicted cure after 5 weeks of therapy in the only modeled participant who achieved a sustained virological response. However, cure was also predicted for two participants who relapsed following treatment. The modeling results confirm that longer than 6 weeks of SOF + R is needed to reach cure in individuals with recent HCV infection. Prospective real-time modeling under current potent DAA regimens is needed to validate the potential of response-guided therapy in the management of recent HCV infection. •Modeling identifies chronic hepatitis C patients who were cured with a reduced duration of direct-acting antivirals (DAA).•Duration of DAA treatment has not been previously modeled in persons with recent (&lt;12 months) hepatitis C infection.•We retrospectively modeled ultra-short (6-week) sofosbuvir + ribavirin therapy in recently infected persons.•Modeling might help identify persons with recent hepatitis C who are appropriate for ultra-short duration of DAA therapy.</description><subject>Direct-acting antivirals</subject><subject>Hepatitis c virus</subject><subject>Mathematical modeling</subject><subject>Recent infection</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkU9rGzEQxUVpaZy0n6F77GUd_VutdCkE06SFhF7Ss9BKY1tmLW0lrUO-fbU4BHLKadDMb96I9xD6RvCaYCKuD2sTij_5ZMY1xXTpcinoB7Qisqetwkp8RKtKipZ1nF6gy5wPGGPRK_kZXTDaKSqpWqHHh-hg9GHXDCaDaxLkKYYMzW72rr7LHpKZnhsfmjwPB7AlN0--7CtoIZRmD5MpvvjcbCqzrXMfwxf0aWvGDF9f6hX6e_vzcfOrvf9z93tzc99a3tHSGsX4MPRMcC6BqEGCwdwRaxR2lrBtbwnthLTEDh2jHPcKegcSCyNZxwbBrtCPs-40D0dwy4eqIXpK_mjSs47G67eT4Pd6F0-6Z9UlIqvA9xeBFP_NkIs--mxhHE2AOGdNOZGESMkXtD-jNsWcE2xfzxCsl0z0Qb9mopdM9DmTunlz3oRqxclD0tl6CBacryYW7aJ_V-M_IXeZwQ</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Gorstein, Evan</creator><creator>Martinello, Marianne</creator><creator>Churkin, Alexander</creator><creator>Dasgupta, Swikriti</creator><creator>Walsh, Kevin</creator><creator>Applegate, Tanya L.</creator><creator>Yardeni, David</creator><creator>Etzion, Ohad</creator><creator>Uprichard, Susan L.</creator><creator>Barash, Danny</creator><creator>Cotler, Scott J.</creator><creator>Matthews, Gail V.</creator><creator>Dahari, Harel</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3357-1817</orcidid><orcidid>https://orcid.org/0000-0001-5691-1557</orcidid></search><sort><creationdate>20200801</creationdate><title>Modeling based response guided therapy in subjects with recent hepatitis C infection</title><author>Gorstein, Evan ; Martinello, Marianne ; Churkin, Alexander ; Dasgupta, Swikriti ; Walsh, Kevin ; Applegate, Tanya L. ; Yardeni, David ; Etzion, Ohad ; Uprichard, Susan L. ; Barash, Danny ; Cotler, Scott J. ; Matthews, Gail V. ; Dahari, Harel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-a934bb736448e19b8ea04d1ca90dc13f7c12568c1cb5324079e7de806a8353b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Direct-acting antivirals</topic><topic>Hepatitis c virus</topic><topic>Mathematical modeling</topic><topic>Recent infection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gorstein, Evan</creatorcontrib><creatorcontrib>Martinello, Marianne</creatorcontrib><creatorcontrib>Churkin, Alexander</creatorcontrib><creatorcontrib>Dasgupta, Swikriti</creatorcontrib><creatorcontrib>Walsh, Kevin</creatorcontrib><creatorcontrib>Applegate, Tanya L.</creatorcontrib><creatorcontrib>Yardeni, David</creatorcontrib><creatorcontrib>Etzion, Ohad</creatorcontrib><creatorcontrib>Uprichard, Susan L.</creatorcontrib><creatorcontrib>Barash, Danny</creatorcontrib><creatorcontrib>Cotler, Scott J.</creatorcontrib><creatorcontrib>Matthews, Gail V.</creatorcontrib><creatorcontrib>Dahari, Harel</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gorstein, Evan</au><au>Martinello, Marianne</au><au>Churkin, Alexander</au><au>Dasgupta, Swikriti</au><au>Walsh, Kevin</au><au>Applegate, Tanya L.</au><au>Yardeni, David</au><au>Etzion, Ohad</au><au>Uprichard, Susan L.</au><au>Barash, Danny</au><au>Cotler, Scott J.</au><au>Matthews, Gail V.</au><au>Dahari, Harel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modeling based response guided therapy in subjects with recent hepatitis C infection</atitle><jtitle>Antiviral research</jtitle><date>2020-08-01</date><risdate>2020</risdate><volume>180</volume><spage>104862</spage><epage>104862</epage><pages>104862-104862</pages><artnum>104862</artnum><issn>0166-3542</issn><eissn>1872-9096</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>Authors Contributions: Study concept and design: MM, GVM, HD. Acquisition of data: MM, TA, GVM. Analysis and interpretation of data: EG, SD, KW, HD. Drafting of manuscript: EG, AC, SD, SLU, DB, SJC, HD. Critical revision of the manuscript for important intellectual content: MM, DY, OE, SJC, GVM, HD. Statistical and modeling analyses: EG, AC, SD, KW, DB, HD. Study supervision: HD.</notes><abstract>Mathematical modeling of viral kinetics has been shown to identify patients with chronic hepatitis C virus (HCV) infection who could be cured with a shorter duration of direct-acting antiviral (DAA) treatment. However, modeling therapy duration has yet to be evaluated in recently infected individuals. The aim of this study was to retrospectively examine whether modeling can predict outcomes of six-week sofosbuvir (SOF) and weight-based ribavirin (R) therapy in individuals with recent HCV infection. Modeling was used to estimate viral host parameters and to predict time to cure for 12 adults with recent HCV infection (&lt;12 months of infection) who received six weeks of treatment with SOF + R. Modeling results yielded a 100% negative predictive value for SOF + R treatment response in nine participants and suggested that a median of 13 [interquartile range: 8–16] weeks of therapy would be required for these patients to achieve cure. Modeling predicted cure after 5 weeks of therapy in the only modeled participant who achieved a sustained virological response. However, cure was also predicted for two participants who relapsed following treatment. The modeling results confirm that longer than 6 weeks of SOF + R is needed to reach cure in individuals with recent HCV infection. Prospective real-time modeling under current potent DAA regimens is needed to validate the potential of response-guided therapy in the management of recent HCV infection. •Modeling identifies chronic hepatitis C patients who were cured with a reduced duration of direct-acting antivirals (DAA).•Duration of DAA treatment has not been previously modeled in persons with recent (&lt;12 months) hepatitis C infection.•We retrospectively modeled ultra-short (6-week) sofosbuvir + ribavirin therapy in recently infected persons.•Modeling might help identify persons with recent hepatitis C who are appropriate for ultra-short duration of DAA therapy.</abstract><pub>Elsevier B.V</pub><pmid>32592829</pmid><doi>10.1016/j.antiviral.2020.104862</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3357-1817</orcidid><orcidid>https://orcid.org/0000-0001-5691-1557</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0166-3542
ispartof Antiviral research, 2020-08, Vol.180, p.104862-104862, Article 104862
issn 0166-3542
1872-9096
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7387218
source ScienceDirect Freedom Collection
subjects Direct-acting antivirals
Hepatitis c virus
Mathematical modeling
Recent infection
title Modeling based response guided therapy in subjects with recent hepatitis C infection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T05%3A39%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modeling%20based%20response%20guided%20therapy%20in%20subjects%20with%20recent%20hepatitis%20C%20infection&rft.jtitle=Antiviral%20research&rft.au=Gorstein,%20Evan&rft.date=2020-08-01&rft.volume=180&rft.spage=104862&rft.epage=104862&rft.pages=104862-104862&rft.artnum=104862&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2020.104862&rft_dat=%3Cproquest_pubme%3E2418118848%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-a934bb736448e19b8ea04d1ca90dc13f7c12568c1cb5324079e7de806a8353b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2418118848&rft_id=info:pmid/32592829&rfr_iscdi=true